CALL/MODERNA/120/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 02:25:05 2024-06-14 pm EDT | ||
| 1.79 EUR | -27.53% |
|
| Current month | -15.96% | ||
| 1 month | +55.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 1.79 | -27.53% |
| 24-06-13 | 2.47 | -10.51% |
| 24-06-12 | 2.76 | +0.73% |
| 24-06-11 | 2.74 | +5.38% |
| 24-06-10 | 2.6 | -9.41% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 02:25 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Goldman Sachs |
| WKN | GZ9BGQ |
| ISIN | DE000GZ9BGQ4 |
| Date issued | 2023-02-27 |
| Strike | 120 $ |
| Maturity | 2024-06-21 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 4.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.74 € |
|---|---|
| Lowest since issue | 0.213 € |
| Spread | 0.05 € |
| Spread % | 2.58% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Warrants
- Warrant
